Previous Article | Next Article ![]()
Journal of Clinical Microbiology, September 2005, p. 4820-4822, Vol. 43, No. 9
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.9.4820-4822.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Bacterial and Mycotic Diseases, Respiratory Diseases Branch,1 Scientific Resources Program, Biotechnology Core Facility Branch, Centers for Disease Control and Prevention, Atlanta, Georgia2
Received 29 April 2005/ Returned for modification 30 May 2005/ Accepted 8 June 2005
|
|
|---|
|
|
|---|
1.2 million deaths among young children, mostly in developing countries (6). Immunity to pneumococcal infection is largely type specific with 90 distinct immunological types being described (4). However, not all known serotypes cause serious infections;
15 serotypes cause the majority of invasive pneumococcal disease worldwide (3). Although this increases the probability of developing effective vaccines targeting the most frequent types, the distribution of serotypes can vary with age, geography, and time, posing greater challenges for vaccine development. Therefore, monitoring the changes in seroepidemiology of this organism is important, especially to evaluate the effect of newer vaccines. Conventionally, serotyping is performed using the standard capsular reaction test (12), although the high cost of antisera and the technical expertise required are limitations of the system. The development of PCR-based serotyping systems has overcome some of the difficulties associated with serologic testing (1, 9), although most of the PCR systems described are limited to identifying serogroups that include cross-reacting serotypes (e.g., they can identify serotypes 6A and 6B only as serogroup 6), leading to incomplete serotype identification. The availability of the sequences of the capsular biosynthetic loci (cps) from all 90 pneumococcal serotypes at the website www.sanger.ac.uk and development of newer techniques such as pyrosequencing for accurate determination of single nucleotide polymorphisms (SNPs) may resolve this issue. Pyrosequencing is a real-time DNA sequencing technique for generating short reads rapidly and inexpensively (13). The method employs coupled enzymatic reactions to detect inorganic pyrophosphate (PPi) released as a result of nucleotide incorporation by DNA polymerase. The released PPi is converted to ATP by ATP sulfurylase, which provides the energy for luciferase to oxidize luciferin and generate light that is detected by a charge-coupled device camera and is seen as a peak in the pyrogram (7, 8, 13).
Recently, the difference between serotypes 6A and 6B has been putatively correlated with a single nonsynonymous substitution in the putative rhamnosyl transferase gene (wciP) (11). We utilized this information to test a pyrosequencing assay to reliably differentiate types 6A and 6B among isolates initially deduced as serogroup 6 from a PCR assay.
Primers targeting a wciP gene segment of types 6A and 6B, which encompasses the putative key polymorphism at codon 195 (see GenBank accession AF246897), were designed using the pyrosequencing assay design software (Biotage AB). wciP-f (5' AATTTGTATTTTATTCATGCCTATATCTGG) (biotinylated at 5' end) and wciP-r (5' TTAGCGGAGATAATTTAAAATGATGACTA) were used to amplify a 250-bp product. PCR was done in 25-µl volumes with 1x PCR buffer (Promega Inc., WI), 2.5 mM of MgCl2, and 200 µM of each deoxynucleoside triphosphate (New England Biolabs, MA) with 250 nM of each primer and 2.0 U of Taq DNA polymerase (Promega Inc., WI). Thermal cycling was performed with the following conditions: 94°C for 4 min and 30 amplification cycles of 94°C for 45 s, 55°C for 45 s, and 65°C for 2 min. Products were detected on 2% NuSieve agarose gels (Cambrex Bio Science, Inc., Rockland, ME). Since multiplex PCR-based serotyping may become a viable alternative to conventional serotyping (1, 9), we incorporated primers wciP-f and wciP-r into a multiplex PCR also containing primers targeting cps loci of three of the most predominant serotypes seen in the Centers for Disease Control and Prevention's (CDC's) Active Bacterial Core surveillance (see http://www.cdc.gov/ncidod/dbmd/abcs/) during 2002 and 2003 (types 19A, 3, and 22F). The primer sequences, product sizes, and concentrations used for the reaction are listed in Table 1. All 250-bp PCR products obtained using the multiplex reaction were identified as serogroup 6 and were stored at 4°C until further use in pyrosequencing.
|
View this table: [in a new window] |
TABLE 1. List of oligonucleotide primers used in the multiplex PCR
|
Two hundred ten serogroup 6 isolates obtained through Active Bacterial Core surveillance were included for analysis (2). These included sterile-site isolates from both adults and children obtained during 2002 and 2003. In the first phase of this study, 175 isolates were amplified in PCRs containing wciP-f and wciP-r and subsequently pyrosequenced with wciP-s. Of the 175 products tested by pyrosequencing, 86 were identified as serotype 6B (Fig. 1) and 88 were serotype 6A (Fig. 1), correlating perfectly with conventional serotyping results. Though the genetic diversity among the isolates in this set was not determined, the strains of serotypes 6A and 6B have been previously found to be genetically diverse (5), and the assay can therefore be used to reliably differentiate serotypes even among strains with high genetic diversity. Only one isolate among our isolate set was consistently identified as serotype 6A by pyrosequencing and not 6B as originally recorded by serotyping. Repeat serotyping revealed that the original results were in error and that the isolate was actually type 6A.
![]() View larger version (32K): [in a new window] |
FIG. 1. The pyrograms indicate the two polymorphic sites that were consistently associated with serotypes 6A and 6B. The regions above each graph correspond to the specific SNPs used for differentiation. The two 25-base wciP coding sequence segments from the type 6A and 6B isolates examined during this work are depicted. The key residue within rhamnosyl transferase that putatively determines the key structural difference between the 6B and 6A serotypes is underlined (8).
|
Accurate determination of pneumococcal serotypes is a continuing priority, especially since the introduction of the heptavalent pneumococcal conjugate vaccine (PCV7). Monitoring of serotypes subsequent to introduction of the highly effective PCV7 is necessary to record the decline in vaccine types while simultaneously detecting possible serotype replacements with nonvaccine types. Though capsular testing has long been the preferred method for serotyping, the subjectivity in interpretation and the technical expertise required make alternate approaches attractive (1). The development of multiplex PCR systems that are rapid, reliable, and cost-effective has the capacity to make serotyping more affordable in resource-limited settings.
Pyrosequencing assays might generally allow distinguishing serotypes within strains that can currently only be serogrouped using PCR-based techniques. It is possible that similar assays can be developed to deduce the serotypes within other cross-reacting serogroups (e.g., serogroups 12, 18, 22, and 7). The assay described here rapidly and reliably detected the key polymorphism believed to be the genetic basis of the structural difference between the serotype 6A and 6B capsules (10). Though the initial setup costs for pyrosequencing are considerable, the cost per test is low at less than $1 (United States). With pyrosequencing finding greater application for diagnosis of infectious and noninfectious diseases (10, 14), the cost may drop with time, making it more affordable. This is the first report on the use of pyrosequencing for deducing serotypes of S. pneumoniae and highlights the possibility of developing multiplex pyrosequencing systems for rapid and reliable determination of pneumococcal serotypes.
We sincerely thank the Active Bacterial Core surveillance investigators for providing the clinical isolates used in the study. We thank the CDC National Vaccine Program Office and the CDC Antimicrobial Resistance Working Group for the necessary resources for this work. We are grateful to Robert E. Gertz for technical assistance.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»